Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1)
Source: View publication →
In a landmark phase 3 trial involving cisgender women in sub-Saharan Africa, twice-yearly subcutaneous lenacapavir was 100% efficacious for HIV preexposure prophylaxis (PrEP), demonstrating zero incident HIV infections and overwhelming superiority over both background incidence and daily oral F/TDF.
Key Findings
Study Design
Study Limitations
Clinical Significance
PURPOSE-1 is a paradigm-shifting trial that establishes twice-yearly lenacapavir as a highly potent, remarkably convenient PrEP option. By completely overcoming the behavioral barrier of daily pill adherence—a factor that has severely limited the real-world effectiveness of oral PrEP in adolescent girls and young women—lenacapavir has the potential to drastically alter the trajectory of the global HIV epidemic, provided there is equitable global access and rapid rollout.
Historical Context
Since the FDA approval of daily oral F/TDF for PrEP in 2012, uptake and adherence among cisgender women—who account for a disproportionate share of global HIV infections, particularly in sub-Saharan Africa—have remained profoundly limited due to structural barriers, stigma, and the difficulty of daily pill-taking. The HPTN 084 trial previously demonstrated the superiority of an every-2-month injectable (cabotegravir) over oral PrEP, validating the long-acting injectable approach. PURPOSE-1 extends this paradigm significantly with lenacapavir, a novel multistage HIV-1 capsid inhibitor with an ultra-long pharmacokinetic profile that enables unparalleled twice-yearly dosing.
Guided Discussion
High-yield insights from every perspective
Lenacapavir is a novel agent for HIV prevention. How does its mechanism of action differ fundamentally from traditional oral PrEP agents like emtricitabine/tenofovir disoproxil fumarate (F/TDF), and why does this allow for its unique twice-yearly dosing schedule?
Key Response
This tests foundational knowledge of the viral life cycle and pharmacology. Traditional PrEP agents like F/TDF are nucleoside reverse transcriptase inhibitors (NRTIs) that halt viral DNA synthesis. Lenacapavir is a first-in-class capsid inhibitor that disrupts multiple stages of the viral life cycle, including nuclear entry and virion assembly. Its unique chemical structure and low aqueous solubility allow it to form a slow-release depot when injected subcutaneously, enabling ultra-long-acting twice-yearly dosing.
Given the 100% efficacy of twice-yearly lenacapavir in the PURPOSE 1 trial, what are the primary clinical indications, adverse effects, and practical follow-up considerations when counseling a high-risk cisgender woman deciding between lenacapavir and daily oral F/TDF?
Key Response
Residents must translate trial efficacy into clinical practice. While efficacy is superior due to guaranteed adherence over 6 months, residents must counsel patients on practical aspects such as injection site reactions (nodules, pain), the necessity of reliable 6-month clinic follow-ups, and the critical importance of not missing a dose to avoid the pharmacokinetic 'tail' period where subtherapeutic drug levels could select for viral resistance if an exposure occurs.
The pharmacokinetic 'tail' of long-acting injectables like lenacapavir poses a theoretical risk for incident HIV with selected resistance if dosing is delayed or discontinued. How should breakthrough infections be monitored and managed to prevent the emergence of capsid inhibitor-resistant strains?
Key Response
Fellows should grasp advanced PK/PD and resistance mechanisms. Lenacapavir's long half-life means subtherapeutic levels persist for months after the last dose. A breakthrough infection during this period could select for resistance, compromising lenacapavir as a future therapeutic option. Monitoring requires sensitive HIV RNA assays rather than just standard antibody testing, and rapid transition to a fully suppressive, non-cross-resistant ART regimen is crucial if infection occurs.
The PURPOSE 1 trial demonstrated overwhelming superiority of lenacapavir over daily oral PrEP, primarily driven by adherence challenges with daily pills. As a clinic director, how do you foresee integrating this twice-yearly injection into existing healthcare delivery models, and what systemic barriers must be overcome to ensure equitable access?
Key Response
Attendings focus on systems-based practice and implementation. The scientific victory of 100% efficacy is clear, but real-world implementation requires addressing high medication costs, establishing clinic infrastructure for subcutaneous depot injections, maintaining patient tracking for semi-annual visits, and proactively dismantling disparities so that marginalized populations are not restricted to oral options while wealthier populations access injectables.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
PURPOSE 1 utilized a recent HIV infection incidence counterfactual (background incidence) rather than a pure placebo group due to ethical constraints of withholding proven PrEP. What are the methodological strengths and limitations of this counterfactual approach, and how does it impact the causal inference of the superiority finding?
Key Response
PhDs must analyze complex trial architectures. Using a Recency Assay-derived background incidence is ethically mandatory but introduces strong assumptions about the comparability of the counterfactual cohort to the trial cohort. Methodological limitations include potential confounding by temporal trends in community transmission and the Hawthorne effect, where trial participation itself alters sexual behavior, potentially skewing the baseline risk estimate and the exact magnitude of the calculated effect size.
The Data and Safety Monitoring Board halted the blinded phase of PURPOSE 1 early due to overwhelming efficacy. As an editor reviewing this manuscript, what specific data would you demand regarding adherence metrics in the active control (F/TDF and F/TAF) arms to ensure the superiority claim reflects a true pharmacological breakthrough rather than merely a failure of adherence in the comparator groups?
Key Response
Editors scrutinize claims of 'superiority.' In PrEP trials involving young African women, adherence to daily oral pills is historically poor. If the oral arms in PURPOSE 1 had near-zero adherence, lenacapavir is functionally being compared to placebo. An editor would flag the need for objective adherence markers (e.g., intracellular tenofovir diphosphate levels) to clarify whether the trial proves lenacapavir's pharmacological superiority or simply confirms the massive adherence advantage of a semi-annual injectable.
Current WHO guidelines recommend daily oral PrEP as the standard, with long-acting cabotegravir (CAB-LA) recently added as an alternative. Based on PURPOSE 1 demonstrating zero infections, what level of evidence does this provide, and what specific criteria (e.g., cost-effectiveness, programmatic feasibility) must be met before guidelines elevate twice-yearly lenacapavir to a preferred, Tier 1 global PrEP recommendation?
Key Response
Guideline developers must weigh efficacy against cost and feasibility. The evidence for lenacapavir's efficacy is high quality (Grade A). However, to update guidelines like the WHO consolidated guidelines on HIV prevention, the committee must evaluate real-world feasibility, generic licensing agreements for low-and-middle-income countries, supply chain requirements, and cost-effectiveness modeling comparing twice-yearly lenacapavir to cheaper, generic daily F/TDF and every-two-month CAB-LA.
Clinical Landscape
Noteworthy Related Trials
Partners PrEP Trial
Tested
Daily oral TDF or TDF/FTC
Population
HIV-1 serodiscordant heterosexual couples
Comparator
Placebo
Endpoint
Incident HIV infections
HPTN 084 Trial
Tested
Long-acting injectable cabotegravir every 8 weeks
Population
Cisgender women at high risk for HIV
Comparator
Daily oral TDF/FTC
Endpoint
Incident HIV infections
DISCOVER Trial
Tested
Daily oral F/TAF
Population
Men who have sex with men and transgender women at risk for HIV
Comparator
Daily oral F/TDF
Endpoint
Incident HIV infections
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis